Fig. 3From: Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in AustriaEstimated CIN2/3 incidences (related to types 16, 18, 6, 11, 31, 33, 45, 52, and 58) over 100Â yearsBack to article page